



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 37/18, A61K 38/00, C07K 2/00, 4/00, 5/00, 7/00, 14/00, 16/00, 17/00	A1	(11) International Publication Number: WO 97/01959 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/US96/11375 (22) International Filing Date: 1 July 1996 (01.07.96) (30) Priority Data: 114407 30 June 1995 (30.06.95) IL (71) Applicant (for all designated States except US): YEDA RE- SEARCH AND DEVELOPMENT CO. LTD. (IL/IL); P.O. Box 95, 76100 Rehovot (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): COHEN, Irm, R. (US/IL); 11 Hankin Street, 76344 Rehovot (IL). ELIAS, Dana (IL/IL); 57 Derech Yavne, 78344 Rehovot (IL). ABU- LAFIA, Rivka (IL/IL); 31/11 Weizmann Street, 56000 Yahud (IL). BOCKOVA, Jana (CZ/US); c/o Joan Fraser, NYS/Pediatrics, SUNY Health Sciences Center, 11th floor, Room 040, Stony Brook, NY 11794 (US). (74) Agent: BROWDY, Roger, L.; Browdy and Neimark, P.L.L.C., Suite 300, 419 Seventh Street N.W., Washington, DC 20004 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NOVEL PEPTIDES DERIVED FROM HUMAN HEAT SHOCK PROTEIN 60 FOR TREATMENT OF DIABETES, COMPOSITIONS, METHODS AND KITS		
(57) Abstract <p>Novel peptides which are epitopes of the human 60 kDa heat shock protein (hsp60) may be used for the diagnosis and treatment of insulin-dependent diabetes mellitus (IDDM). Pharmaceutical compositions containing such peptides and kits for use in diagnosis of IDDM are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NOVEL PEPTIDES DERIVED FROM HUMAN HEAT SHOCK PROTEIN 60
FOR TREATMENT OF DIABETES, COMPOSITIONS, METHODS AND KITS

FIELD OF THE INVENTION

5 The present invention relates to novel peptides
being epitopes of the human 60KDa heat shock protein (hsp 60)
and to pharmaceutical compositions comprising them for the
diagnosis and treatment of insulin-dependent diabetes mellitus
(IDDM).

BACKGROUND OF THE INVENTION

10 Type I diabetes, or IDDM, is an autoimmune disease
caused by T cells that attack and destroy the insulin-
producing β -cells located in the islets of the pancreas
15 (Castano and Eisenbarth, 1990). The autoimmune process
culminating in IDDM begins and progresses without symptoms.
The disease surfaces clinically only when the cumulative loss
of β -cells exceeds the capacity of the residual β -cells to
supply insulin. Indeed, the collapse of glucose homeostasis
20 and clinical IDDM is thought to occur only after 80-90% of the
 β -cells have been inactivated by the immune system. Thus,
patients who can be identified as suffering from IDDM are
bound to be in an advanced stage of autoimmune destruction of
their β -cells. Moreover, diagnosis of incipient, pre-
25 clinical diabetes by the detection of immunological markers of
 β -cell autoimmunity can be made only after the onset of the
autoimmune process. Therefore, the therapeutic quest is to
find a safe, specific and effective way to turn off an
autoimmune process that is already well underway.

30 The present inventors have examined this question
before by studying the spontaneous diabetes developing in mice
of the NOD strain, which is considered to be a faithful model
of human IDDM (Castano and Eisenbarth, 1990). NOD mice
develop insulinitis around 4 weeks of age, which begins as a
35 mild peri-islet infiltrate and progresses to severe intra-
islet inflammation. Hyperglycemia, which attests to insulin
insufficiency, begins in the females in our colony at about
14-17 weeks of age. By 35-40 weeks of age, almost all the

female NOD mice have developed severe diabetes and most die in the absence of insulin treatment. Male NOD mice have a lower incidence of disease, for reasons that are not clear. The diabetes of NOD mice has been shown to be caused by autoimmune T cells (Bendelac et al., 1987).

T cell reactivity and autoantibodies to various antigens have been detected in human IDDM patients as well as in NOD mice (Elias, 1994), and it is not clear whether immunity to any single one of the possible target antigens is the primary cause of the disease. Beyond the question of causation is the question of therapy.

It has been demonstrated that the initiation of the autoimmune process in NOD mice can be prevented by subjecting the mice, before the onset of diabetes, to various manipulations such as restricted diet, viral infections, or non-specific stimulation of the immune system (Bowman et al., 1994). NOD diabetes is also preventable by induction of immunological tolerance in pre-diabetic mice to the antigen glutamic acid decarboxylase (Kaufman et al., 1993; Tisch et al., 1993).

Insulin dependent diabetes mellitus (IDDM) developing spontaneously in NOD female mice has been associated with immune reactivity to a variety of self-antigens (Bach, 1994). Notable among these antigens is the p277 peptide from the sequence of the mammalian 60 kDa heat shock protein (hsp60) molecule. This corresponds to residues 437-460 in the human hsp60 molecule (Elias et al 1991, Israel Patent Application No. 94241, PCT patent publication WO90/10449). The human p277 peptide has the following sequence:

Val-Leu-Gly-Gly-Gly-Cys-Ala-Leu-Leu-Arg-Cys-Ile-
Pro-Ala-Leu-Asp-Ser-Leu-Thr-Pro-Ala-Asn-Glu-Asp
(a.a. 437-460 of SEQ ID NO:1).

Pre-diabetic NOD mice manifest spontaneous, diabetogenic T cell responses to hsp60 and to the human (2) or mouse variants of the p277 peptide (3). The mouse and human peptides differ by 1 amino acid and are immunologically cross-reactive (3). Some non-diabetes prone strains of mice, such

as C57BL/6, develop transient hyperglycemia and insulinitis when immunized to p277 covalently conjugated to a foreign immunogenic carrier molecule (4). And mice of the C57BL/KsJ strain develop spontaneous T-cell responses to hsp60 and to p277 after treatment with a very low dose of the β -cell toxin streptozotocin (STZ) that induces autoimmune diabetes (5).

In addition to being involved in the expression of the disease, peptide p277 appears to be functional in healing the autoimmune process: Subcutaneous administration of p277 in incomplete Freund adjuvant (IFA; mineral oil) led to arrest of disease progression in young NOD mice (2) or in 12-17 week old NOD mice with advanced insulinitis (6, 7). Both the human (6, 7) and mouse (3) variants of p277 were effective. NOD mice transgenic for the mouse hsp60 gene on an MHC class II promoter showed down-regulation of their spontaneous T-cell proliferative response to p277 and a significant proportion of the mice were spared the development of diabetes (8). Moreover, administration of p277 to C57BL/KsJ mice aborted the development of autoimmune diabetes in mice that had received earlier a very low dose of STZ; treatment of these mice with a peptide of the GAD65 molecule was not effective (9).

Variants of the p277 peptide in which one or both cysteine residues at positions 6 and 11 were replaced by valine residues, designated as p277(Val⁶), p277(Val¹¹) and p277(Val⁶-Val¹¹), respectively, were described in corresponding Israel Patent Application No. 112094, and shown to be as active as p277 in the treatment of diabetes.

It is an object of the present invention to provide additional peptides of human hsp60, such peptides being useful for diagnosis and treatment of IDDM.

SUMMARY OF THE INVENTION

In a study of fragments and peptides of the human hsp60 molecule, it was unexpectedly found that IDDM patients and NOD mice are responsive to other hsp60 T-cell epitopes that may be used for diagnosis and therapy of IDDM. These epitopes, by themselves or in conjunction with p277 or a p277

variant selected from p277(Val⁶), p277(Val¹¹) and p277(Val⁶-Val¹¹), may improve the efficacy of the treatment.

These new peptides are identified in Table 1.

5 Table 1- Hsp60 Synthetic Peptides and Their Sequence

	<u>Peptides</u>	<u>Residue nos. of SEO ID NO:1</u>	<u>Amino acid sequence (one letter code)</u>
	p3	31-50	KFGADARALMLQGVDLLADA
10	p10	136-155	NPVEIRRGVMLAVDAVIAEL
	p11	151-170	VIAELKKQSKPVTTPPEIAQ
	p12	166-185	EEIAQVATISANGDKKEIGNI
	p14	195-214	RKGVITVKDGTKLNDELEII
	p18	255-274	QSIVPALEIANAHKKPLVIIA
15	p20	286-305	LVLNRLKVGQLQVVAVKAPGF
	p24	346-365	GEVIVTKDDAMLLKGGDKA
	p29	421-440	VTDALNATRAAVEGIVLGG
	p30	436-455	IVLGGGCALLRCIPALDSLT
	p32	466-485	EIIKRTLKIPAMTIKNAGV
20	p35	511-530	VNMVEKGIIDPTKVVRTALL
	p39	343-366	GKVGIVVTKDDAM

Other peptides of hsp60, including those designated p278 (corresponding to positions 458-474 in the human hsp60 sequence), p19 (corresponding to positions 271-290 in the human hsp60 sequence), and p21 (corresponding to positions 301-320 in the human hsp60 sequence) were shown not to be as effective. It is noted that the amino terminus of p278 overlaps with the effective p277 peptide by three residues (NED) and the carboxy terminus of p278 overlaps with the effective p32 peptide by 9 residues (EIIKRTLKI). Thus, the remaining 11 residues of p32 are critical (PAMTIKNAGV).

The present invention thus relates to the peptides identified in Table 1, and salts and functional derivatives thereof.

It is further an object of the present invention to provide methods and kits for the early diagnosis of IDDM using the peptides of the invention. In the course of developing

IDDM, animals express hsp60 molecules, or molecules which are cross-reactive therewith, which find their way into the blood and urine of the animals. They also express antibodies and T cells directed specifically to such molecules. Thus, the
5 presence of hsp60 (or molecules which are cross-reactive therewith) or antibodies or T cells specific thereto in blood or urine, serves as an assay for the detection of the IDDM process before the destruction of beta cells is completed and the individual is doomed to life-long diabetes.

10 The presence or incipience of IDDM in a patient can be diagnosed by testing the blood or urine of said patient for the presence of antibodies or T cells which are immunologically reactive with human hsp60, using as antigen a peptide p12 or p32 of the invention.

15 Accordingly, the present invention provides a method for diagnosing the presence or incipience of IDDM in a patient, comprising testing said patient for the presence of anti-hsp60 antibodies or of a T cell which immunoreacts with hsp60 using a peptide of the present invention as antigen,
20 whereby a result indicating the positive presence of anti-hsp60 antibodies or of a T cell which immunoreacts with hsp60, indicates a high probability of the presence or incipience of IDDM.

25 In the method for diagnosing IDDM, the patient may be tested for the presence of anti-hsp60 antibodies, wherein said test method may comprise a radioimmunoassay or an ELISA test.

30 The patient may also be tested for the presence of a T cell which immunoreacts with hsp60. In one embodiment of this aspect, the test method comprises a T cell proliferation test comprising the steps:

(i) preparing a mononuclear cell fraction containing T cells from a blood sample obtained from said patient;

(ii) adding to said mononuclear cell fraction an
35 antigen selected from the peptide of the invention;

(iii) incubating said cell fraction in the presence of said antigen for a suitable period of time and under suitable culture conditions;

(iv) adding a labeled nucleotide to the incubated cell culture of (iii) at a suitable time before the end of said incubation period to provide for the incorporation of said labeled nucleotide into the DNA of proliferating T cells;
5 and

(v) determining the amount of proliferating T cells by analysis of the amount of labeled nucleotide incorporated into said T cells.

In step (iv) above, said labeled nucleotide is preferably ³H-thymidine. The determination of the amount of proliferating T cells is made by calculation of the stimulation index of the T cells by standard methods.

In another embodiment of this aspect of the invention, the test method comprises a T-cell cytokine response test, in which steps (i) to (iii) are as in the above T cell proliferation test, and in a fourth step (iv) the presence of cytokine, such as IFN- γ , IL-2, IL-4, IL-6, IL-10, TNF α or TGF β , secreted by the responding lymphocytes into the medium, is detected by standard methods with
15 commercially available kits.

In another aspect, the invention provides an *in vivo* method wherein an antigen selected from the peptides of the invention is injected subcutaneously into a patient and the occurrence of a detectable skin reaction (delayed type hypersensitivity; DTH) is observed.
25

The present invention also relates to means for performing such assays, as well as kits for performing such assays. The kits may be prepared for carrying out any of the various assays used for accomplishing the present invention.
30 Each such kit includes all of the materials necessary to conduct a single assay or a fixed number of assays. For example, such a kit for determining the presence of anti-hsp60 antibodies may contain a solid-phase immobilized peptide of the invention and a tagged antibody capable of recognizing the non-variable region of the anti-hsp60 antibody to be detected,
35 such as tagged anti-human Fab. The kit may also contain directions for using the kit and containers to hold the materials of the kit. Any conventional tag or label may be

used, such as a radioisotope, an enzyme, a chromophore or a fluorophore. A typical radioisotope is iodine-125 or sulfur-35. Typical enzymes for this purpose include horseradish peroxidase, horseradish galactosidase and alkaline phosphatase.

A kit for diagnosing the presence of IDDM by testing for the presence of anti-hsp60 antibodies, comprises:

- (i) an antigen selected from the peptides of the invention; and
- (ii) a tagged antibody capable of recognizing the non-variable region of said anti-hsp60 antibodies to be detected.

A kit for diagnosing the presence of IDDM by testing for the presence of a T cell which immunoreacts with hsp60, will comprise:

- (i) an antigen selected from the peptides of the invention;
- (ii) a suitable medium for culture of lymphocytes (T cells); and
- (iii) either a labeled nucleotide for the T cell proliferation test, or a cytokine, e.g., interferon-gamma, assay kit, for the cytokine test.

For the *in vivo* test, the kit will comprise only a peptide of the invention in a suitable form for injection.

- The present invention further relates to means for preventing or treating IDDM. Vaccination with an antigen peptide of the present invention can provide a specific down regulation of autoimmunity to the antigen, and effectively creates a resistance to the autoimmune process of IDDM. The same is true with respect to vaccination with T cells specific to such antigens, in attenuated or avirulent form or after having been treated to improve their antigenicity, or fragments or active fractions thereof. If the patient is shown to already be in the pre-clinical incipient stages of IDDM, injection with such an antigen or T cell (or fraction) can create a down regulation of autoimmunity for this antigen and thus arrest the autoimmune process before significant, permanent damage is done. The peptide can also be used as a

therapeutic agent to arrest the autoimmune process even after it is far advanced, as shown recently by the laboratory of the present inventors regarding the treatment of NOD mice with the peptide p277 (Elias and Cohen, 1994).

- 5 Accordingly, the present invention provides a preparation for preventing or treating insulin-dependent diabetes mellitus (IDDM), comprising: (a) T cells which have developed specificity for a protein or peptide which is immunologically cross-reactive with a peptide of the
10 invention, which cells have been activated by incubating in the presence of said peptide; (b) said T cells which have been irradiated or otherwise attenuated; (c) said T cells which have been subjected to pressure treatment by means of hydrostatic pressure, treatment with a chemical cross-linking
15 agent and/or treatment with a cytoskeletal cross-linking agent; (d) fragments of or surface proteins shed from (a), (b) or (c); or (e) a peptide consisting essentially of the variable region of the receptor of (a) specific for said protein, or a salt, functional derivative, precursor or active
20 fraction thereof.

In a preferred embodiment of the invention, the preparation comprises human T cells that have developed specificity by *in vitro* contact with said peptide of the invention.

- 25 The present invention also provides a pharmaceutical composition for the prevention or treatment of IDDM comprising a pharmaceutically acceptable carrier and, as active principle, an effective amount of a peptide of the invention, a salt or a functional derivative thereof.

- 30 The invention further relates to a method of preventing or treating IDDM which comprises administering to a patient in need thereof a pharmaceutical composition comprising a peptide of the invention, a salt or a functional derivative thereof, or a preparation comprising T cells which
35 have developed specificity to said peptide of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the positions of the peptides referred to herein on the entire sequence of the human hsp60 molecule.

Fig. 2 shows NOD mouse T-cell proliferation to human hsp60 peptides p12, p32, p277(Val¹-Val¹¹) and p278.

Fig. 3 is a graph showing T-cell proliferative responses of NOD mice to peptides. Groups of three NOD mice were immersed with peptides mouse p12, mouse p277, GAD-p35 and MT-p278 in IFA each at a dose of 25 μ g in IFA. The draining lymph nodes were removed 10 days later and assayed for proliferative responses to the corresponding peptide at the concentrations of 5, 10, 20, and 50 μ g/ml. The stimulation at the optimal concentration of 20 μ g/ml is shown. The following ranges of cpm were obtained in medium controls: mouse p12, 881; mouse p277, 1243; MT-p278, 698 and GAD-p35 1430. Peptide mouse p38 is a peptide derived from mouse hsp60 (556-573), which has no sequence homology with the tested peptides and serves as a negative control of specificity. These results are representative of the three experiments performed. Each assay was done in triplicates for which the SD values are indicated by the bars. There was no cross-reactivity between the peptides (not shown).

Fig. 4 is a graph showing the effect of peptide administration on diabetes. Groups of 10-20 NOD mice were treated at 10 weeks of age with 100 μ g of mouse p12, p277, p35-GAD or MT-p278 in IFA, or IFA alone. The mice were bled monthly and followed for the onset of hyperglycemia. As compared to the IFA treated control group, the mice treated with p12 and p277 were significantly protected, $P < 0.05$.

Fig. 5 shows the IgG1, IgG2a and IgG2b antibody isotypes in response to peptide treatment. Mice were treated as described in the legend to Figure 4. Individual samples were analyzed for antibodies to mouse p12 A; p277 B; GAD-p35 C; and MT-p278 D, of the IgG1, IgG2a and IgG2b isotypes. Similar effects were obtained in two experiments. The results are presented as the absorbance at 405nm (OD) of 10 individual mice in each group. The level of significance of the

prevalence of IgG1 and IgG2b antibodies in groups A and B compared to C and D is $P < 0.001$. The differences between the levels of IgG1 and IgG2b antibodies compared to the IgG2a antibodies in groups A and B were significant ($P < 0.001$).

5 There was no cross-reactivity between the antibodies (not shown)

Fig. 6 shows the negative correlation between antibodies and blood glucose. A group of NOD female mice were treated with p12 (10 mice) or with IFA alone (9 mice) as described in the legend to Figure 4. The amount of anti-p12 specific antibody (ELISA O.D units in sera diluted 1:50, measured at 7 months of age) is plotted together with the blood glucose concentration measure at 7 months of age. The degree of correlation between high antibodies and blood
10 glucose is $P < 0.002$.

Fig. 7 is a graph showing T-cell proliferative responses (S.I.) of one IDDM patient donor to recall antigens, to hsp60 protein, and to hsp60 synthetic peptides.

Fig. 8 is a graph showing T-cell proliferative
20 responses (S.I.) of a healthy donor to recall antigens, to hsp60, and to hsp60 synthetic peptides.

Fig. 9 is a graph showing T-cell proliferative responses (S.I.) of another IDDM patient donor to recall antigen, to hsp60 and to hsp60 synthetic peptides.

25 Figs. 10A and 10B are graphs showing T-cell proliferative responses (S.I.) of two IDDM patient donors to hsp60 synthetic peptides.

DETAILED DESCRIPTION OF THE INVENTION

30 Whenever "peptide of the invention" or any of the individual designations, such as "peptide p12" or "peptide p32" is mentioned in the present specification and claims, also salts and functional derivatives thereof are contemplated, as long as the biological activity of the
35 peptide with respect to diabetes is maintained.

"Salts" of the peptides of the invention contemplated by the invention are physiologically acceptable organic and inorganic salts.

"Functional derivatives" of the peptides of the invention as used herein covers derivatives which may be prepared from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e., they do not destroy the activity of the peptide, do not confer toxic properties on compositions containing it and do not adversely affect the antigenic properties thereof.

These derivatives may, for example, include aliphatic esters of the carboxyl groups, amides of the carboxyl groups produced by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed by reaction with acyl moieties (e.g., alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free hydroxyl group (for example that of seryl or threonyl residues) formed by reaction with acyl moieties.

The peptides of the invention can be used as immunogen in pharmaceutical compositions, particularly vaccines for the alleviation and treatment of IDDM, as well as an antigen in diagnostic compositions for the diagnosis of IDDM. These pharmaceutical and diagnostic compositions, which may be prepared in a manner known in the art, also form part of the present invention.

The therapeutic composition in accordance with the present invention may be administered orally or parenterally, such as subcutaneously, intramuscularly, intravenously, intranasally or intrarectally.

The invention will now be illustrated in a non-limitative manner by the following Examples and accompanying figures.

EXAMPLES

Materials and Methods

(i) Mice. Inbred female mice of the NOD/Lt strain were supplied by the Animal Breeding Center of the Weizmann Institute of Science, Rehovot, Israel, or by the Jackson

Laboratory, Bar Harbor, ME. These mice spontaneously develop autoimmune diabetes at 14 to 17 weeks of age that mimics IDDM in humans.

- (ii) **Antigens.** Peptides were synthesized in the Department of Organic Chemistry of the Weizmann Institute of Science using an automated multiple peptide synthesizer (Abimed model AMS 422; Langenfeld, Germany) following the company's protocols for N- α -fluorenylmethoxycarbonyl (Fmoc) synthesis. Crude products were purified by reversed phase HPLC on a semi-preparative C8-column (Lichrosorb RP-8, 7 mm, 250 x 10 mm, Merck, Darmstadt, Germany). Elution of peptides was achieved by linear gradients established between 0.1 % trifluoroacetic acid in water and 0.1 % trifluoroacetic acid in 75 % acetonitrile in water (v/v). The purity of the single peptide products was ascertained by analytical reversed-phase HPLC and amino acid analysis. Peptide MT-p278 is from the sequence of Mycobacterial hsp60 (431-447). Peptide p277 is substituted at positions 6 and 11 with valine (V) in place of the cysteine (C) in the native sequence. Substitution of the two C residues by V enhances greatly the stability of the peptide without affecting its immunological activity: the V-substituted peptide is completely cross-reactive with the native peptide by T-cell and antibody assays. Whenever unspecified, the human sequence is intended. The mouse p12 and mouse p38 peptides are derived from the mouse hsp60 molecule and correspond to its 168-188, 437-460 and 556-573 sequences, respectively. Peptide GAD-p35 is from the GAD65 molecule (524-543). The amino acid sequences of all of the peptides used herein are shown in Table 2.

Table 2 - Synthetic Peptides and Their Sequences

	<u>Peptides</u>	<u>Sequence ID No:</u>	<u>Amino acid sequence (one letter code)</u>
5	p3	1 (31-50)	KFGADARALMLQGVDLLADA
	p10	1 (136-155)	NPVEIRRGVMLAVDAVIAEL
	p11	1 (151-170)	VI AELKKQSKPVTTP EEIAQ
	p12	1 (166-185)	EEIAQVATISANGDK EIGNI
	p14	1 (195-214)	RKGVITVKD GKT LNDELEII
10	p18	1 (255-274)	QSIVPALEIANAH RKPLV IIA
	p20	1 (286-305)	LVLNRLKVG LQV VAVKAPGF
	p24	1 (346-365)	GEVIVTKDDAMLLKGKGDKA
	p29	1 (421-440)	VTDALNATRAA VEEGIVLGG
	p30	1 (436-455)	IVLGGGCALLRCIPALDSL T
15	p32	1 (466-485)	EIIKRTLKIPAMTIAKNAGV
	p35	1 (511-530)	VNMVEKGIIDPTKVVRTALL
	p39	1 (343-366)	GKVGEVIVTKDDAM
	p19	1 (271-290)	LVIIAEDVDGEALSTLV LNR
	p21	1 (301-320)	KAPGFGDNRNQ LKDMAIAT
20	p278	1 (458-474)	NEDQKIGIEI I KRTLKI
	p277(Val)	2	VLGGGVALLRVIPALDSLTPANED
	mouse p12	3	EEIAQVATISANGDKDIGNI
	MT-p278	4	EGDEATGANIVKVALEA
	GAD-p35	5	SRLSKVAPVIKARMM EYGT T
25	mouse p38	6	PGMGAMGGMGGG MGGGMF

(iii) T-Cell proliferation to peptides.

Mice. Nine week old NOD mice or mice of other strains were immunized in the hind foot pads with 0.1 ml of an emulsion containing 25 µg peptide in complete Freund's adjuvant (CFA; Difco, Detroit, MI.) mixed with an equal volume of phosphate-buffered saline (PBS). The draining popliteal lymph nodes were removed 10 days later and suspensions of lymphocytes in triplicate cultures were tested for proliferation in the presence of the various peptides (5 µg/ml) using the incorporation of [³H]-thymidine as described (Elias et al., 1991). The results are shown as the stimulation index (SI): the ratio of the mean cpm in the

presence of the test peptide to the mean cpm of control cultures without the peptide. Standard errors were always less than 10% of the means.

(iv) Treatment and follow-up. Peptides, 100 mg, in PBS, were emulsified with an equal volume of IFA and injected subcutaneously into 10-week-old NOD females as described (Elias and Cohen, 1995). Control mice received an equal volume of PBS emulsified in IFA. The mice were monitored monthly for non-fasting blood glucose at 10am using the Blood Glucose Sensor (MediSense, Inc., Waltham, MA). Mice with a blood glucose greater than 11.1 mmol/L were considered to be diabetic; this concentration of glucose was greater than 3 standard deviations above the mean blood glucose concentration measured in non-diabetic mice (Elias and Cohen, 1995). Histological examination of the islets of the pancreas was done on sections stained with hematoxylin and eosin. The sections were scored independently by two observers who both were unaware of the identity of the groups. The chi square test was used to ascertain the statistical differences between the various treatments.

(v) Serum Antibodies. Mice were bled monthly to detect antibody responses. The ELISA assay was done as described (Elias et al., 1991). Briefly, flat bottom Maxi-sorb plates (Nunc, Roskilde, Denmark) were coated, for the detection of anti-peptide antibodies, with 100 µl/well of peptide in PBS, at a concentration of 10 mg/ml for 2 h at room temperature followed by over night incubation at 4°C. After incubation with peptide, the plates were washed and blocked for 2 h at 37°C with 7% BSA (Sigma) in PBS. Sera were diluted 1:50 then added for 2 h at 37°C, followed by incubation for 2 h with 100 µl per well of goat anti-mouse IgG (gamma chain Fc specific) conjugated to alkaline phosphatase (Jackson, Philadelphia, PA). After washing, the plates were incubated with the substrate, diethanolamine (Sigma) and read using an ELISA reader at 405 nm.

EXAMPLE 1Mapping of hsp60 epitopes in NOD mice

The immunogenicity of the hsp60 peptides p12, p32, p277(Val⁶-Val¹¹) and p278 in NOD mice was tested by immunizing the mice with the peptides emulsified in CFA in the hind foot pads, and assaying the proliferative responses of draining lymph node cells after 10 days as described above in section iii(a). As shown in Fig. 2, the peptides p277(Val⁶-Val¹¹), p12 and p32 were strongly immunogenic, while p278 was non-immunogenic.

EXAMPLE 2Treatment of NOD mice with p277(Val⁶-Val¹¹), p12 or p32

To test whether the p12 and p32 peptides can block the progression of diabetes as p277(Val⁶-Val¹¹), the p277(Val⁶-Val¹¹), p12 or p32 peptides (100 µg in a 0.1 cc emulsion of IFA) were administered subcutaneously to groups of 10-12 nine-week old NOD/Lt female mice of the Jackson Laboratory, Bar-Harbor, ME. Diabetes, determined as persistent blood glucose levels over 11.1 mmol/l, was tested at 25 weeks of age. Control mice were untreated or were treated with p278.

As shown in Table 1, p277(Val⁶-Val¹¹), p12 and p32 were effective in treatment of diabetes, the incidence of diabetes in untreated mice or in p278-treated mice being 90%, while p277(Val⁶-Val¹¹), p12 and p32-treated mice show an incidence of 10%, 20% and 30%, respectively. On the other hand, the control p278 peptide had no therapeutic effect.

Table 3
Therapeutic effect of hsp60 peptides

	Peptide	Diabetes (%)	Mortality (%)	Number of Recipients
5	none	90	50	100
	p278	90	45	100
	p277(Val ⁶ -Val ¹¹)	10*	5*	100
	p12	20*	10*	10
10	p32	50*	25*	20

* P<0.05

It is possible that a combination of two or three hsp60 epitope peptides will be more effective than only one peptide, as more T-cell populations will be affected by the therapy.

EXAMPLE 3

Newly diagnosed IDDM patients show T-cell proliferative responses to hsp60, p277(Val⁶-Val¹¹), p12 and p32

To determine the T-cell responses to the various hsp60 peptides, lymphocytes from the peripheral blood of newly diagnosed (2 weeks-4 months) IDDM patients were tested in a proliferation assay. 10-20 ml of blood were removed into a sterile tube containing heparin as anti-coagulant and diluted in PBS 1:2. Peripheral mononuclear cells (PBMC) were isolated by centrifuging the blood over a lymphoprep layer. The PBMC were tested for proliferation in triplicates, in the presence of the various antigens (10 µg/ml) for 6 days using the incorporation of [³H]-thymidine as a measure of proliferation. The antigens tested were human hsp60 or the hsp60 peptides p277(Val⁶-Val¹¹), p12, p32 and control peptide p278. The T cell proliferative response is depicted as stimulation index (SI): The ratio between peptide-stimulated thymidine incorporation and background (no antigen added) thymidine incorporation by the T cells.

The results are summarized below in Table 4.

Table 4

Patient		T-cell proliferative response(SI)				
to:		hsp60	p277(V)	p12	p32	p278
5	1	5.6	4.5	4.0	1.1	0.5
	2	7.5	5.0	4.5	1.3	0.8
	3	8.0	5.6	1.2	7.1	0.7
10	4	3.4	1.0	1.9	2.9	0.9
	5	1.2	1.1	1.7	1.0	N.D.
	6	6.7	1.3	5.2	4.5	N.D.
	7	10.3	3.9	1.2	6.0	N.D.
	8	1.3	1.2	1.5	1.1	N.D.

- 15 A stimulation index (SI) of more than 2.0 is considered a positive response.

N.D. = Not determined; p277(V) = p277(Val⁶-Val¹¹)

- 20 It can be seen that most of the patients responded to hsp60 (6/8) and that all of the six that responded to hsp60 also responded to at least one of the three hsp60 peptides: p12, p32 or p277(Val⁶-Val¹¹). Thus, a response to the group of the peptides can serve to characterize the individuals responding to the whole hsp60 molecule.

25 EXAMPLE 4

T cell proliferative responses

- Spontaneous T cell responses in pre-diabetic NOD mice were detected to the mouse p277 peptide (Elias et al., 1991; Birk et al., 1996) and to larger fragments of the mouse hsp60 molecule that contained the mouse p277 sequence (Birk et al., 1996). To detect other T-cell epitopes on the mouse hsp60 molecule, NOD mice were immersed with pools of peptides overlapping the hsp60 sequence and found that all mice made strong response to both mouse p277 and to mouse p12 (Figure 3). Other peptides immunogenic for NOD mice are the MT-p278 peptide (residues 458-474 in the Mycobacterial hsp60 molecule), and GAD-p35 (residues 524-543 in the GAD65 molecule). Figure 3 shows that MT-p278 is as strongly

immunogenic as are mouse p277 and mouse p12; GAD-p35 is also immunogenic, but less so.

5 A longitudinal study of female NOD mice at ages 3-16 weeks showed no spontaneous responses to mouse p12 in their spleens (not shown), although responses to mouse p277 and to whole mouse hsp60 were seen. Thus, of four immunogenic peptides: p12 and p277 from the mouse hsp60 molecule, GAD-p35 from the diabetes-associated GAD65 molecule, and MT-p278, a foreign immunogen, spontaneous responses were detected only to mouse p277 and to MT-p278.

Peptide Treatment

Following a protocol shown to be effective with mouse p277 (Elias et al., 1991; Elias and Cohen, 1994; Elias and Cohen, 1995), groups of 10-week old female NOD mice were treated by a single subcutaneous injection of each peptide (100 mg) emulsified in IFA. The mice were observed for the development of diabetes through 8 months of age. Figure 4 shows that peptides mouse p277 and mouse p12 were both effective in inhibiting the development of diabetes ($P < 0.05$). In contrast, treatment with peptides MT-p278 or GAD-p35 was no different than was treatment with IFA alone. A total of 3 experiments showed essentially the same results.

Antibodies

Successful treatment of STZ-induced diabetes with mouse peptide p277 was associated with the appearance of anti-peptide antibodies predominantly of the IgG1 and IgG2b isotypes (Elias and Cohen, 1996). The peptide-treated NOD mice for their serum antibodies was therefore examined. Figure 5 shows that the two peptides effective in arresting diabetes, mouse p12 and mouse p277, were also effective in inducing strong antibody titers of the IgG1 and IgG2b isotypes ($P < 0.001$). The IgG1 and IgG2b antibody titers were also significantly greater than the IgG2a antibody titers in these groups ($p < 0.001$). The mice treated with peptides MT-p278 or GAD-p35 did not respond as strongly; none of the GAD-p35-

treated mice made specific IgG1 antibodies and only two of the ten MT-p278-treated mice made antibodies of the IgG1 isotype. The mice treated with MT-p278 or GAD-p35 made significantly lower titers of IgG2b antibodies ($P < 0.001$). Thus, effectiveness in inhibiting diabetes was associated with the induction of an antibody response mainly of the IgG1 and IgG2b isotypes.

The relationship between an effective therapeutic response and the titer of antibody was confirmed by a comparison of the concentration of the blood glucose with the concentration of antibodies in individual mice at 7 months of age. Figure 6 shows that the mice with higher titers of anti-mouse p12 antibodies tended to have lower blood glucose concentrations; conversely, the mouse p12-treated mice that made little antibody to mouse p12 tended to have high blood glucose ($P < 0.002$).

DISCUSSION

The results presented in this example indicate that peptide p12 of the mouse hsp60 molecule, like peptide p277, can be effective in treating mice close to the outbreak of overt hyperglycemia. In contrast to p277, spontaneous T-cell proliferative responses to p12 in the spleens of pre-diabetic NOD mice were not observed. Thus, a spontaneous anti-peptide proliferative response detectable in the periphery is not a requirement for a peptide to be effective in blocking the diabetic autoimmune process.

The finding that peptide p277 is not the only hsp60 peptide that can modulate NOD diabetes is significant. It was conceivable that the involvement of hsp60 in NOD diabetes could have come about by mimicry between the p277 peptide of hsp60 and some unknown molecule more specific for β -cells (Cohen, 1991). However it is highly unlikely that two different segments of hsp60, p277 and p12, could both mimic segments of the proposed, but unknown β -cell molecule. The effectiveness of p12 in peptide treatment supports the conclusion that the hsp60-like molecule functional in diabetes is hsp60 itself (Birk et al., 1996).

The failure of peptide MT-p278 and GAD-p35 to arrest the development of diabetes indicates that not any self-antigen or any spontaneously T-cell proliferating antigen can be used to abort the autoimmune process. It is interesting, that MT-p278 failed to induce high-titers of antibodies or protect, despite the fact that their peptide is strongly immunogenic for T cells (unpublished observation). However, the induction of antibodies of any specificity does not necessarily affect NOD diabetes; treatment of NOD mice with BSA, which induces high titers of antibodies as well as strong T cell responses (not shown), does not affect the development of diabetes (Elias and Cohen, 1994). Although GAD-p35 was not found by us to be as strongly immunogenic for T cells as were the other peptides (Figure 3). NOD mice have been reported to manifest spontaneous T cell responses to their peptide (Kaufman et al., 1989).

Finally, the association of effective treatment with induction of antibody specific to the peptide suggests that the therapeutic effects of p12 and p277 might be related to the activation of Th2-type T cells responsible for helping the induction of specific IgG1 antibodies, antibodies regulated by the production of IL-4 (Mossman and Coffman, 1993). Such T cells could suppress the Th1 T cells thought to be proposed to be responsible for damaging the β -cells (Katz et al., 1995; Liblau et al., 1995). Indeed, it has been found that p277 peptide therapy of NOD diabetes is associated with a burst of IL-4 and IL-10 producing T cells in the spleen and a fall in the T cells producing INF- γ both in the spleen and in the islets (unpublished observation). The appearance of peptide-specific antibodies bearing Th2 isotypes in response to peptide therapy appears to be an indicator of a beneficial response.

EXAMPLE 5 - Additional Peptides to Which IDDM Patients can Manifest T-cell Responses

Twenty six newly diagnosed (1 to 16 weeks after IDDM diagnosis) IDDM patients were enrolled. Patients' ages ranged from 5 to 60 years old. The patients were screened for their

peripheral blood T-cell proliferative responses to human hsp60, and to human hsp60 synthetic peptides shown in Tables 1 and 5, which are portions of the human hsp60 protein sequence.

5 The patients' T-cells were analyzed also for their proliferative responses to standard recall antigens such as tetanus toxoid, *Candida albicans* and influenza, and the responses were scored as positive if the stimulation index (S.I.) was 2 or greater (see below).

10 Proliferation was assayed using the following protocol:

Cell Preparation and Cell Proliferation Protocol

 Fifty ml of peripheral blood supplemented with 10
15 IU/ml heparin was drawn from IDDM patients or from healthy controls. Two volumes of PBS (calcium- and magnesium-free) were added. The blood-PBS preparation was mixed using a 10 ml pipette. A volume of 10 ml Ficoll was underlaid in the blood mixture, followed by centrifugation at 2,000 rpm for 30
20 minutes at room temperature (R.T.) 20-24°C (brake off). The peripheral blood T-cells in the buffy coat were harvested using a 10 ml pipette and transferred to a new 50 ml test tube. A volume of 30 to 40 ml PBS (calcium- and magnesium-free) was added to the harvested T-cells. This was then mixed
25 and centrifuged at 1,000 rpm for 20 minutes at R.T. (brake on).

 The supernatant was aspirated, and the pellet of cells was resuspended in AIM-V serum free culturing media (GIBCO, USA). The culture medium contains AIM-V supplemented
30 with 1% sodium-pyruvate, 1% L-glutamine (200 mM each), 1% penicillin/streptomycin (10,000 U/ml / 10,000 mg/ml and 2% Hepes (1 M, pH 7.3). Alternatively, RPMI supplemented with 10% AB serum from the blood bank was used. The cell mixture was then centrifuged at 2,000 rpm for 10 minutes at R.T.
35 (brake on). The supernatant was again aspirated and the pellet of cells resuspended in a smaller volume of fresh AIM-V (10-20 ml). The cells were resuspended and counted. Cell counting

and viability assays were performed using trypan blue. For this step a hemocytometer and a light microscope were used.

The cell concentration was then adjusted to 2×10^6 cells/ml in AIM-V media. A volume of 100 μ l of the cells per well were transferred to each well of a 96-well microtiter plate. Then, 100 μ l of media containing two-fold the recommended antigen concentration (see below list of antigens and concentrations) was added. The assay was performed in quadruplicate. Four wells were assayed with cells and media without antigen as a control. The plates were cultured at 37 C° in a 5% CO₂ humidified incubator for 7 days. On day 6 of the culturing period, 1 μ Ci/well of ³H-thymidine was added. The cultures were continued for 18 hours and then harvested. Cell proliferation was assayed by ³H-thymidine incorporation to DNA, determined using scintillation liquid and a beta counter reader.

Antigens Tested

Concentration

20	Tetanus toxoid (Connaught Lab. Inc. Pen. USA)	5 g/ml
	<i>Candida albicans</i> (Miles, WA. USA)	20 μ g/ml
	Recombinant human hsp60 (StressGen, Canada)	2-5 μ g/ml
	Human hsp60 synthetic peptides	20 μ g/ml

25 Proliferative responses were measured according to the 'thymidine ³H incorporated by T cells' DNA (Elias et al., 1991). Radioactive counts per minute (CPM) were compared between cells cultured with the tested antigens or without antigen (media only) as a control. The proliferation values were represented as a stimulation index value (S.I.): mean CPM with the antigen divided by the mean CPM without the antigen. S.I. values greater than or equal to 2 were considered to be positive.

35 The results showed that the incidence of human hsp60 or hsp60-peptide reactive individuals was higher among IDDM patients (84%) than among healthy people (30%). The Fisher Exact Test p value of the difference is 0.0044, which is highly significant.

Proliferative responses of two representative IDDM patients and of one healthy individual, to human hsp60 protein, to hsp60 synthetic peptides, and to various recall antigens are shown in Fig 7, 8, and 9. Table 5 shows two individual examples of hsp60 synthetic peptides (p19, p21) to which no IDDM patients responded (see also Figs. 10A and 10B).

It can be seen that each of the patients responded to recall antigens (*Candida*, tetanus, or influenza) and to human hsp60 protein and to various human hsp60 peptides. The control person responded only to control recall antigens.

The sequences of the hsp60 synthetic peptides to which at least one of the IDDM patients responded are shown in Table 1. Each of these peptides has therapeutic potential for treating IDDM.

Table 5
Hsp60 Synthetic Peptides and Their Sequence to Which IDDM Patients

<u>Peptides</u>	Did Not Respond	
	<u>Residue nos.</u> <u>of SEQ ID NO:1</u>	<u>Amino acid sequence</u> <u>(one letter code)</u>
p19	271-290	LVIIAEDVDGEALSTLVLR
p21	301-320	KAPGFQDNRKQQLKDMAIAT

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that

the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

5

10

15

20

25

30

35

REFERENCES

- Bach JF. (1994) Insulin-Dependent Diabetes Mellitus as an Autoimmune Disease. Endocrine Reviews 15:516-542.
- Bendelac A, Carnaud C, Boitard C, Bach JF. (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Ly+2+ T cells. J Exp Med. 166: 823-32.
- Birk OS, Elias D, Weiss AS, Rosen A, van-der Zee R, Walker MD, Cohen IR. (1996) NOD mouse diabetes: The ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J. Autoimmun. 9:159-166.
- Bowman MA, Leiter EH and Atkinson MA. (1994) Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunology Today. 15:115-20.
- Castano L, Eisenbarth GS. (1990) Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol. 8:647-79.
- Cohen IR. (1991) Autoimmunity to chaperonins in the pathogenesis of arthritis and diabetes. Annu Rev Immunol 9:567-589.
- Elias, Dana. (1994) The NOD mouse: A model for autoimmune insulin-dependent diabetes. Autoimmune Disease Models, A Guidebook, pp 147-61.
- Elias D, Cohen IR. (1995) Treatment of autoimmune diabetes and insulinitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 44:1132-1138.
- Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. (1991) Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65 kDa heat shock protein. Proc. Natl Acad Sci USA. 88:3088-91.
- Elias D. and Cohen IR. (1994) Peptide therapy for diabetes in NOD mice. The Lancet. 343:704-706.
- Elias D, Cohen IR. (1996) The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozocin. Diabetes (in press).
- Katz JD, Benoist C, Mathis D. (1995) T helper cell subsets in insulin-dependent diabetes. Science 268:1185-1188.

Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV. (1993) Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 366:69-72.

Liblau RS, Singer SM, McDevitt HO. (1995) Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38.

Mossman TRR, Coffman RL. (1989) TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 9:145-173.

Tisch R, Yang XD, Singer SM, Liblav RS, Fuggar L, McDevitt HO. (1993) Immune response to glutamic acid decarboxylase correlates with insulinitis in non-obese diabetic mice. Nature. 366:72-75.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: YEDA RESEARCH & DEVELOPMENT CO. LTD. at the
Weizmann Institute of Science

(B) STREET: P.O. Box 95
(C) CITY: Rehovot
(E) COUNTRY: Israel
(F) POSTAL CODE (ZIP): 76 100
(G) TELEPHONE: 972-8-9470617
(H) TELEFAX: 972-8-9470739

(A) NAME: Irun R. COHEN
(B) STREET: 11 Hankin Street
(C) CITY: Rehovot
(E) COUNTRY: Israel
(F) POSTAL CODE (ZIP): 76354

(A) NAME: Dana ELIAS
(B) STREET: 57 Derech Yavne
(C) CITY: Rehovot
(E) COUNTRY: Israel
(F) POSTAL CODE (ZIP): 78344

(A) NAME: Rivka ABULAFIA
(B) STREET: 31/11 Weizmann Street
(C) CITY: Yahud
(E) COUNTRY: Israel
(F) POSTAL CODE (ZIP): 56000

(A) NAME: Jana BOCKOVA c/o Ms. Joan Fraser,
NYS/Pediatrics, SUNY Health Sciences Center
(B) STREET: 11th Floor, Room 040
(C) CITY: Stony Brook
(D) STATE: N.Y.
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 11794

(ii) TITLE OF INVENTION: NOVEL PEPTIDES DERIVED FROM HUMAN HEAT SHOCK
PROTEIN 60 FOR TREATMENT OF DIABETES, COMPOSITIONS,
METHODS AND KITS

(iii) NUMBER OF SEQUENCES: 6

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: IL 114407
(B) FILING DATE: 30-JUN-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 573 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Leu Arg Leu Pro Thr Val Phe Ala Gln Met Arg Pro Val Ser Arg
 1 5 10 15

Val Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
 20 25 30

Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
 35 40 45

Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
 50 55 60

Glu Gln Gly Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
 65 70 75 80

Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
 85 90 95

Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
 100 105 110

Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
 115 120 125

Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
 130 135 140

Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
 145 150 155 160

Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
 165 170 175

Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
 180 185 190

Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
 195 200 205

Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
 210 215 220

Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
 225 230 235 240

Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser
 245 250 255

Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
 260 265 270

Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu
 275 280 285

Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
 290 295 300

Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
 305 310 315 320

Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp
 325 330 335

Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
 340 345 350

Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu
 355 360 365
 Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu
 370 375 380
 Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly
 385 390 395 400
 Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu
 405 410 415
 Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val
 420 425 430
 Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile
 435 440 445
 Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly
 450 455 460
 Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala
 465 470 475 480
 Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln
 485 490 495
 Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn
 500 505 510
 Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala
 515 520 525
 Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Val
 530 535 540
 Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala
 545 550 555 560
 Met Gly Gly Met Gly Gly Gly Met Gly Gly Met Phe
 565 570

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Val Leu Gly Gly Gly Val Ala Leu Leu Arg Val Ile Pro Ala Leu Asp
 1 5 10 15
 Ser Leu Thr Pro Ala Asn Glu Asp
 20

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala Asn Gly Asp Lys Asp
1 5 10 15

Ile Gly Asn Ile
20

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Glu Gly Asp Glu Ala Thr Gly Ala Asn Ile Val Lys Val Ala Leu Glu
1 5 10 15

Ala

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ser Arg Leu Ser Lys Val Ala Pro Val Ile Lys Ala Arg Met Met Glu
1 5 10 15

Tyr Gly Thr Thr
20

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Pro Gly Met Gly Ala Met Gly Gly Met Gly Gly Gly Met Gly Gly
1 5 10 15

Met Phe

CLAIMS

1. A peptide selected from the peptides identified in Table 1, and salts and functional derivatives thereof.
2. The peptide according to claim 1 herein designated p12.
3. The peptide according to claim 1 herein designated p32.
4. Use of a peptide according to claim 1 for the diagnosis of insulin-dependent diabetes mellitus (hereinafter IDDM).
5. A method for diagnosing the presence or incipience of IDDM in a patient, comprising testing the blood or urine of said patient with a peptide according to claim 1 as antigen for the presence of antibodies or T cells which are immunologically reactive with human hsp60.
6. A method according to claim 5, comprising testing said patient for the presence of anti-hsp60 antibodies or of a T cell which immunoreacts with hsp60, whereby a result indicating the positive presence of anti-hsp60 antibodies or of a T cell which immunoreacts with hsp60 indicates a high probability of the presence or incipience of IDDM.
7. A method according to claim 5 or 6, wherein said patient is tested for the presence of anti-hsp60 antibodies.
8. A method according to claim 7, wherein the test method comprises a radioimmunoassay.
9. A method according to claim 7, wherein the test method comprises an ELISA test.

10. A kit for diagnosing the presence of IDDM by testing for the presence of anti-hsp60 antibodies according to the method of any one of claims 5 to 9, comprising:

(i) an antigen being a peptide of the sequences in claim 1; and

(ii) a tagged antibody capable of recognizing the non-variable region of said anti-hsp60 antibodies to be detected.

11. A kit according to claim 10, wherein said antigen is the peptide according to claim 2.

12. A kit according to claim 10, wherein said antigen is the peptide according to claim 3.

13. A kit according to any one of claims 10 to 12, wherein said antigen is immobilized on a solid phase.

14. A kit according to any one of claims 10 to 13, further including instructions for use of the kit in the diagnosis of IDDM.

15. A kit according to any one of claims 10 to 14, wherein the tag is selected from the group consisting of radioisotopes, enzymes, chromophores and fluorophores.

16. A method according to claim 5 or 6, wherein said patient is tested for the presence of a T cell which immunoreacts with hsp60.

17. A method according to claim 16, wherein the test method comprises a T cell proliferation test comprising the following steps:

(i) preparing a mononuclear cell fraction containing T cells from a blood sample obtained from said patient;

(ii) adding to said mononuclear cell fraction an antigen selected from peptide according to claim 1;

(iii) incubating said cell fraction in the presence of said antigen for a suitable period of time and under suitable culture conditions;

(iv) adding a labeled nucleotide to the incubated cell culture of (iii) at a suitable time before the end of said incubation period to provide for the incorporation of said labeled nucleotide into the DNA of proliferating T cells; and

(v) determining the amount of proliferating T cells by analysis of the amount of labeled nucleotide incorporated into said T cells.

18. A kit for diagnosing the presence of IDDM by testing for the presence of a T cell which immunoreacts with hsp60 according to the method of any one of claims 5, 6, and 17, comprising:

(i) an antigen selected from peptide according to claim 1;

(ii) a labeled nucleotide; and

(iii) a suitable medium for culture of lymphocytes.

19. A kit according to claim 18, further including instructions for use of the kit in the diagnosis of IDDM.

20. A method according to claim 16, wherein the test method comprises a T cell cytokine response test comprising the following steps:

(i) preparing a mononuclear cell fraction containing T cells from a blood sample obtained from said patient;

(ii) adding to said mononuclear cell fraction an antigen selected from peptide according to claim 1;

(iii) incubating said cell fraction in the presence of said antigen for a suitable period of time and under suitable culture conditions; and

(iv) measuring the presence of a cytokine secreted by the responding lymphocytes into the medium.

21. A method according to claim 20, wherein the cytokine is IFN- γ , IL-2, IL-4, IL-6, IL-10, TNF α or TGF β .

22. A kit for diagnosing the presence of IDDM by testing for the presence of a T cell which immunoreacts with hsp60 according to the method of any one of claims 5, 6, 20 and 21, comprising:

- (i) an antigen selected from peptide according to claim 1;
- (ii) a suitable medium for culture of lymphocytes; and
- (iii) an assay kit for measuring the presence of the cytokine secreted by the responding lymphocytes into the medium.

23. A kit according to claim 22, further including instructions for use of the kit in the diagnosis of IDDM.

24. A method according to claim 16, wherein an antigen selected from a peptide according to claim 1 is injected subcutaneously into a patient and the occurrence of a detectable skin reaction is observed.

25. A preparation for preventing or treating IDDM, comprising:

- (a) T cells which have developed specificity for a protein or peptide which is immunologically cross-reactive with a peptide according to claim 1, which cells have been activated by incubating in the presence of said peptide;
- (b) said T cells which have been irradiated or otherwise attenuated;
- (c) said T cells which have been subjected to pressure treatment by means of hydrostatic pressure, treatment with chemical cross-linking agent and/or treatment with a cytoskeletal cross-linking agent;
- (d) fragments of or surface proteins shed from (a), (b) or (c); or

(e) a peptide consisting essentially of the variable region of the receptor of (a) specific for said protein, or a salt, functional derivative, precursor or active fraction thereof.

26. A preparation according to claim 25, wherein said T cells of (a) are human T cells, and said specificity of said T cells has been developed by *in vitro* contact with said peptide.

27. A preparation according to claim 25 or 26, wherein said T cells have developed *in vitro* specificity to a peptide according to claim 1.

28. A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition according to claim 28 for the prevention or treatment of IDDM.

30. A pharmaceutical composition according to claim 28 or 29, wherein said peptide is the peptide according to claim 2.

31. A pharmaceutical composition according to claim 28 or 29, wherein said peptide is the peptide according to claim 3.

32. Use of a peptide according to any one of claims 1 to 3 for the preparation of a pharmaceutical composition for the treatment of IDDM.

1/8

1 / 8

1 MLRLPTVTRQ MRPVSRVLAP HLTRAYANDV KFGADARALM LOGVDLLADA ^{p3}

51 VAVTMGPKGT TVIIEQSWGS PKVTKDGVTV AKSIDLKDKY KNIGAKLVQD

101 VANNTNEEAG DGTTTATVLA RSIAGEFEK ISKGANPVEI RRGVMLAUDA ^{p10}

151 VIAETKKQSK PVTTFEEIAO VATISANGDK EIGNIHSDAM KKVGRKGVIT ^{p11 p12}

201 VKDGTKLNDE LEIIEGMKED RGYISPYFIN TSKGQKCEPQ DAYVLLSEKK ^{p14}

251 ISSI OSIVPA LEIANHRKP LVIIAEDVDG EALSTLVINR LKVGLOVVAV ^{p18 p19 p20}

301 KAPGEGDNRK NQLKDMAIAT GGAVFGEEGL TLNLEDVQPH DL GKVGCVTV ^{p21 p39}

351 TKDDAMLLKG KGDKAQIEKR IQEIIQLDV TTSEYEKEKL NERLAKLSDG ^{p24 p30}

401 VAVLKVGGS DVEVNEKKDR VTDALNATRA AVEEGHVLGG GCALLRCIPA ^{p29 p277}

451 LDSLTPANED QKIGIEIKR TLKIPAMTIA KNAGVGSGLI VEKIMQSSSE ^{p278 p32}

501 VGYDAMAGDF VNMVERGIID PTKVVRTALL DAAGVASLLT TAEVVVTEIP ^{p35}

551 KEEKDPGMGA MGGMGGMGG GMF

2 / 8

FIG.2





FIG.3



3 / 8

FIG. 4





FIG. 6



4 / 8

FIG. 5B




FIG. 5D




FIG. 5A






FIG. 5C




5 / 8


FIG. 7



6 / 8

FIG. 8





8 / 8

FIG. 10A





FIG. 10B



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/11375

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 530/300; 514/2,866

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300; 514/2,866

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

protein data search: sequences from Table I

DIALOG (biosis, medline, scisearch, embase, wpi): author and word (diabetes, heat shock protein, hsp60, iddm)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Lancet, Volume 343, issued 19 March 1994, ELIAS et al., "Peptide therapy for diabetes in NOD mice", pages 704-706, see entire document.	1-9, 16-17, 20-21, 24-32
Y	Experientia, Volume 48, issued 1992, YANG et al., "Heat shock proteins in autoimmune disease. From causative antigen to specific therapy?", pages 650-656, see entire document.	1-9, 16-17, 20-21, 24-32

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 SEPTEMBER 1996

Date of mailing of the international search report

11 OCT 1996

Name and mailing address of the ISA/US
Commissioner of Patents and TrademarksBox PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HEATHER BAKALYAR

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/11375

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	The Journal of Immunology, Volume 153, number 3, issued 01 August 1994, SOMOZA et al., "Pancreas in Recent Onset Insulin-Dependent Diabetes Mellitus. Changes in HLA, Adhesion Molecules and Autoantigens, Restricted T Cell Receptor V β Usage, and Cytokine Profile", pages 1360-1377, see entire document.	1-9, 16-17, 20-21, 24-32

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/11375**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 10-15, 18-19, 22-23
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/11375

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01N 37/18; A61K 38/00; C07K 2/00, 4/00, 5/00, 7/00, 14/00, 16/00, 17/00